ERBB2 and neoplasm: The 4-1BB/HER2 bispecific antibody-anticalin fusion PRS-343 was demonstrated to induce growth-inhibition of HER2 positive tumor cells in vivo and infusion of this bispecific agent into cynomolgus monkeys was well tolerated.